Pharmacoeconomic Analysis of Cost Comparison Between Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB) Antihypertensive Drugs in Hospitalized Hypertensive Patients at RSU Royal Prima

Cherryl A.M Simbolon; Razoki; Asyrun Alkhairi Lubis

doi:10.35451/y2fhvc35

Authors

Cherryl A.M Simbolon Universitas Prima Indonesia
Razoki Universitas Prima Indonesia, Medan
Asyrun Alkhairi Lubis Universitas Prima Indonesia, Medan

DOI:

https://doi.org/10.35451/y2fhvc35

Keywords:

Pharmacoeconomics, Antihypertensive, Calcium Channel Blocker (CCB), Angiotensin II Receptor Blocker (ARB), Hospitalized Patients

Abstract

Hypertension is a global health problem that contributes substantially to morbidity and mortality, thus requiring therapeutic management that is both clinically effective and economically efficient. In clinical practice, Calcium Channel Blockers (CCB) and Angiotensin II Receptor Blockers (ARB) are commonly used, either as monotherapy or in combination, but they differ in terms of cost and effectiveness. This study aimed to conduct a pharmacoeconomic analysis by comparing the costs and effectiveness of antihypertensive therapy using CCB and ARB in hospitalized hypertensive patients at RSU Royal Prima Medan. The study employed a retrospective design with a pharmacoeconomic analysis approach. Data were obtained from the medical records of hospitalized hypertensive patients during the period October–December 2024 using a total sampling technique, resulting in 52 patients who received CCB therapy, ARB therapy, or a combination of CCB + ARB. The analysis included patient characteristics, treatment costs, therapeutic effectiveness based on achievement of target blood pressure <140/90 mmHg, and calculation of the Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER). The results showed that the combination therapy of CCB + ARB had the highest total treatment cost, while the lowest average cost per patient was found in the ARB monotherapy group. In terms of effectiveness, CCB monotherapy demonstrated the highest effectiveness (75.0%). ACER analysis indicated that CCB monotherapy was the most cost-effective therapy, and ICER analysis confirmed that CCB dominated both ARB and the CCB + ARB combination. In conclusion, CCB monotherapy is the most cost-effective antihypertensive treatment option for hospitalized hypertensive patients at RSU Royal Prima Medan.

Downloads

Download data is not yet available.

References

[1] Amalia, V. N., & Sjarqiah, U. (2023). Gambaran Karakteristik Hipertensi Pada Pasien Lansia Di Rumah Sakit Islam Jakarta Sukapura Tahun 2020. Muhammadiyah Journal Of Geriatric, 3(2), 62–68.

[2] Ananta, S. C., Kurniawati, S. L., & Hidayah, L. (2024). Analisis Efektivitas Biaya (Cost Effectiveness Analysis) Pengobatan Antihipertensi Kombinasi Pada Pasien Rawat Jalan Di Klinik Pratama Rawat Jalan Salsabila. Java Health Jounal, 11(01), 23–30.

[3] Baroroh, F., Sari, A., Laili, K. Z., & Permatasari, D. P. (2021). Cost-Effectiveness Analysis Of Antihypertensive Drug Use In Hypertension-Diabetes Mellitus And Hypertension-Heart Failure Inpatients At A Government Hospital In Yogyakarta, Indonesia. First International Conference On Health, Social Sciences And Technology (Icohsst 2020), 41–45.

[4] Hadning, I., Riswana, N. U., Ardhani, N. C., & Arini, M. (2025). Cost-Effectiveness Analysis Of Amlodipine And Candesartan Use In Type 2 Diabetes Mellitus Patients With Comorbid Hypertension In Yogyakarta, Indonesia. Jurnal Farmasi Sains Dan Praktis, 147–155.

[5] Paramita, R. W. D., Rizal, N., & Sulistyan, R. B. (2021). Metode Penelitian Kuantitatif. Widya Gama Press.

[6] Putri, A. S., & Dyahariesti, N. (2021). Analisis Efektivitas Biaya Kombinasi Obat Antihipertensi Pada Pasien Rawat Inap Di RS PKU Muhammadiyah Yogyakarta Tahun 2020. Indonesian Journal Of Pharmacy And Natural Product, 4(2).

[7] Riyada, F., Fauziah, S. A., Liana, N., & Hasni, D. (2024). Faktor Yang Mempengaruhi Terjadinya Resiko Hipertensi Pada Lansia. Scientific Journal, 3(1), 27–47.

[8] SHARMA, H., Kumar, A., Kaur, S., Singh, J., & Sharma, G. (2022). Cost Analysis Of Oral Antihypertensive Drugs: Assessing The Effect Of Drug Price Control Order In India. Asian Journal Of Pharmaceutical And Clinical Research, 73–76. Https://Doi.Org/10.22159/Ajpcr.2022.V15i9.46092

[9] Taiso, S. N., Sudayasa, I. P., & Paddo, J. (2021). Analisis Hubungan Sosiodemografis Dengan Kejadian Hipertensi Di Wilayah Kerja Puskesmas Lasalepa, Kabupaten Muna. Nursing Care And Health Technology Journal (NCHAT), 1(2), 102–109.

[10] Udem, N. D., Ike, S. O., & Uhumwangho, M. (2022). Drug Utilization Pattern Of Antihypertensives In A Private Healthcare Setting In Enugu, Nigeria.

[11] World Health Organization. (2025). Hypertension – Fact Sheet. World Health Organization (WHO). Https://Www.Who.Int/News-Room/Fact-Sheets/Detail/Hypertension

[12] Gultom R, Silvia M. Cost minimalization analysis (CMA) penggunaan obat antihipertensi golongan calcium channel blocker kombinasi angiotensin receptor blocker pada pasien hipertensi di RSU Imelda Pekerja Indonesia Medan. JIFI (Jurnal Ilmiah Farmasi Imelda). 2022 Mar 31;5(2):51-6.

[13] Wulandari T, Abriani NG. Analisis Biaya Terapi Obat Kombinasi Antihipertensi pada Pasien Hipertensi Rawat Jalan. Jurnal Stethoscope. 2022 Aug 29;3(1).

[14] Nurizha NP, Supriatna A, Ulwani MA, Khusniyah K, Rahayu MO, Frianto D. Review Artikel: Analisis Efektivitas Biaya Terapi Hipertensi Terapi Obat Amlodipin Dibandingkan Dengan Bisoprolol Pada Pasien Rawat Jalan. Innovative: Journal Of Social Science Research. 2023 Jun 4;3(2):7653-62.

[15] Hidayati, N.R., Susilo, R., Indriaty, S. and Kartika, D., 2022. Analisis Efektivitas Biaya Kombinasi Candesartan-Amlodipin Dengan Candesartan-Furosemide Pasien Hipertensi Rawat Inap Rs Xxx: Cost-Effectiveness Analysis Of Combination Of Candesartan-Amlodipine With Candesartan-Furosemide In Hypertension Patients Xxx Hospital. Medical Sains: Jurnal Ilmiah Kefarmasian, 7(4), pp.951-962.

[16] Sihombing YR, Marbun RA, Zebua KC, Lestari D. The evaluation of the use of anti-inflammatory drugsin patients rheumatoid arthritis outpatient at grandmed hospital lubuk pakam. Jurnal farmasimed (JFM). 2022 Oct 31;5(1):80-6.

[17] Wulandari T, Abriani NG. Analisis Biaya Terapi Obat Kombinasi Antihipertensi pada Pasien Hipertensi Rawat Jalan. Jurnal Stethoscope. 2022 Aug 29;3(1).

[18] Marbun RA, Nainggolan H, Wahyuni S, Sihombing YR, Parinduri AI. Seminar Evaluation of the Use of Antihypertensive Drugs in Hospitalized Patients Suffering From Hypertension in Grandmed Hospital Lubuk Pakam in 2023. JURNAL PENGMAS KESTRA (JPK). 2023 Jun 30;3(1):99-103.

[19] Sihombing YR, Marbun RA, Zebua KC, Lestari D. The evaluation of the use of anti-inflammatory drugsin patients rheumatoid arthritis outpatient at grandmed hospital lubuk pakam. Jurnal farmasimed (JFM). 2022 Oct 31;5(1):80-6.

[20]Marbun RA. The Effect of Drug Inventory Management on the Accuracy of Prescription Services in Pharmaceutical Installations. JURNAL KESMAS DAN GIZI (JKG). 2025 Aug 11;7(2):539-48.